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Key message:	
We performed whole genome sequencing of metastatic sites and primary colorectal cancer (CRC) in 
a patient with synchronous and metachronous metastases and exploited the time of needle tract 
seeding as a stopwatch to determine the timeline of progression. We provide the first experimental 
evidence documenting the timing of synchronous metastases in CRC and show that genomic 
instability might be more important than the metastatic potential of the primary cancer in dictating 
CRC progression.   		 	 	
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Abstract	
Background	
Patients often ask oncologists how long a cancer has been present before causing symptoms or 
spreading to other organs. The evolutionary trajectory of cancers can be defined using phylogenetic 
approaches but lack of chronological references makes dating the exact onset of tumours very 
challenging. 	
Patients and Methods	
Here we describe the case of a colorectal cancer patient presenting with synchronous lung metastasis 
and metachronous thyroid, chest wall and urinary tract metastases over the course of five years. The 
chest wall metastasis was caused by needle tract seeding, implying a known time of onset.	
Using whole genome sequencing data from primary and metastatic sites we inferred the complete 
chronology of the cancer by exploiting the time of needle tract seeding as an in vivo ‘stopwatch’. This 
approach allowed us to follow the progression of the disease back in time, dating each ancestral node 
of the phylogenetic tree in the past history of the tumour. We used a Bayesian phylogenomic 
approach, which accounts for possible dynamic changes in mutational rate, to reconstruct the 
phylogenetic tree and effectively “carbon date” the malignant progression.	
Results	
The primary colon cancer emerged between five and eight years prior to the clinical diagnosis. The 
primary tumour metastasised to the lung and the thyroid within a year from its onset. The thyroid 
lesion presented as a tumour-to-tumour deposit within a benign Hurthle adenoma. Despite rapid 
metastatic progression from the primary tumour, the patient showed an indolent disease course. 
Primary cancer and metastases were microsatellite stable and displayed low chromosomal instability. 	
Conclusion	
Our data provide the first in vivo experimental evidence documenting the timing of metastatic 
progression in colorectal cancer, and suggest that genomic instability might be more important than 
the metastatic potential of the primary cancer in dictating colorectal cancer fate.    		 	 	
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Introduction		
Colorectal cancer (CRC) is the second most common cancer in Europe and the USA [1]. 
Synchronous and metachronous metastases contribute to the high mortality of CRC [2] and, despite 
improvements in the management of metastatic CRC, 5-year mortality remains up to 50% [1, 3, 4] 
with a worse outcome for synchronous versus metachronous metastasis (5-year relative survival 
7.2% versus 17.6%) [2]. Discussion around the optimal management of synchronous metastasis from 
CRC is still open but it is reasonable to hypothesize that the difference in outcome between 
synchronous and metachronous metastases may not be entirely attributable to clinical variables. 
International large-scale sequencing efforts will likely identify cancer pathways associated with the 
molecular makeup of synchronous and metachronous metastatic spread. Critical questions remain 
open: what is the chronological evolution of a synchronously presenting metastatic CRC? Can we 
tailor screening and follow-up strategies according to the expected pattern of metastatic progression?		
Whole Genome Sequencing (WGS) of distinct metastases allows reconstruction of cancer 
evolutionary trees but the lack of defined temporal milestones limits the ability to infer the exact timing 
of cancer progression. 		
Needle tract seeding is a rare but well-documented phenomenon after diagnostic core needle 
biopsies and causes metastatic growth of the cancer along the needle tract [5]. Here we performed 
WGS of primary and multiple metastatic sites of a CRC patient who developed an iatrogenic 
metastasis due to needle tract seeding. Exploiting the mutational load of this metastasis along with 
the exact timing of its onset, we calculated the chronology of the primary CRC and metastatic sites.		
METHODS		
Ethical approval	
FFPE material was acquired under the diagnostic samples/pathology archives surplus to clinical 
requirements protocol at NHS Ayrshire and Arran. The patient provided full written informed consent 
for the analyses as detailed, and for the case to be published. 
 
The full method list can be found online in the Supplementary Material	
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Results 
 
Needle tract seeding as stopwatch to calibrate cancer evolution 	
In September 2008 a 68 year old Caucasian male underwent anterior resection for a pT3pN2(4/17) 
EMVI negative, poorly differentiated adenocarcinoma of the sigmoid colon. Pre-operative staging 
revealed a solitary left upper lobe lung lesion of uncertain significance, which was kept under active 
radiological surveillance for nearly 3 years and remained stable (Fig 1; Supplementary Table 1). 		
Repeat imaging in July 2011 demonstrated an increase in size of the left upper lobe lung lesion in 
addition to a new nodule in the left lobe of the thyroid. CT-guided lung biopsy (December 2011) 
confirmed metastatic colorectal carcinoma with supportive immunohistochemical staining reaction: 
positive for CK20, CDX2 and CEA but negative for TTF-1 (Fig. 1; Fig. 2A and 2B). The patient 
proceeded to left upper video-assisted thoracoscopic lobectomy in January 2012. Left thyroid 
lobectomy (August 2012) demonstrated a follicular Hurthle cell adenoma of the thyroid, within which 
there was a single tumour-to-tumour deposit of metastatic colorectal cancer (Fig. 1; Fig. 2A and 2C). 
The patient underwent periodic follow-up with tumour markers and imaging thereafter and remained 
disease-free. 
 
In September 2013, 5 years from the initial diagnosis, FDG-PET-CT demonstrated a focal 
unresectable left posterior chest wall mass at the site of previous lung biopsy; histology confirmed 
metastatic adenocarcinoma from the sigmoid primary in keeping with seeding of malignant cells from 
the needle biopsy performed two years before. Radical chemo-radiotherapy to the left posterior chest 
wall mass was completed in February 2014 but repeat CT in May and August 2014 demonstrated 
residual disease at this site in addition to a new abnormality in the upper pole of the left kidney. Renal 
and left ureteric biopsy demonstrated metastatic colorectal cancer, with immunohistochemical staining 
positive for CDX2, CK20, CK7 and BerEP4 [(Fig. 1; Fig. 2A and 2D; Supplementary Fig. S1) a 
detailed description of the case can be found in the Supplementary Material]. Primary tumour and 
metastatic deposits showed similar histopathologic characteristics, resembling that of a traditional 
moderately-differentiated (G2) adenocarcinoma. No MSI-like features (i.e. poor differentiation; 
presence of mucinous and signet ring cells differentiation; medullary growth pattern; presence of 
tumour intraepithelial lymphocytes; Crohn’s like lymphocytic reaction) were observed.		
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Genomic profiling	
Targeted sequencing of 409 cancer related genes in both the primary CRC and all metastatic sites 
(lung, thyroid, chest wall and urinary tract) of our case revealed the presence of clonal non-sense 
mutations in APC (Gln1367*), as well as missense mutations in CTNNB1 (Leu156Gln), KRAS 
(Gly12Asp) and TP53 (Ser215Ile) (Supplementary Tables 2 and 3). The same mutations were not 
detected in the normal tissue or in the Hurthle adenoma (Fig. 2E). Two genes included in our panel 
showed discordance between primary and metastatic cancer: ADAMTS20, a metalloproteinase 
involved with cancer invasion and migration [6], and AKAP9 an A-kinase anchor protein which binds 
to the regulatory subunit of protein kinase A [7]. The ADAMTS20 missense mutation Arg1885Thr was 
observed in the primary cancer but was not detected in either the lung, thyroid or chest wall 
metastases. Conversely, the AKAP9 missense mutation Ala3077Pro was found in all the metastatic 
sites but was not detected in the primary cancer.	 	All these mutations were also found using WGS 
furthermore ADAMTS20 and AKAP9 were validated by Sanger Sequencing (Supplementary Fig. S2). 
All lesions were microsatellite stable (MSS) [8]. Copy number analysis based on WGS data revealed 
a relative low level of chromosomal instability, with LOH of chromosome 5, gain of chromosome 7, 
and a focal amplification on chromosome 13q12.2-12.3, encompassing the VEGFR1 [9] and CDX2 
[10] genes (Fig. 2F; Supplementary Fig. S3 and Supplementary Table S4). These aberrations were 
clonal in all the CRC lesions, whereas the Hurthle adenoma showed a distinct profile characterised 
only by loss of chr2, chr9 and chr22. Primary tumour and metastatic sites displayed the same 
dominant age related mutational signature 1 which has previously observed in CRC as well as other 
cancer types [ref Alexandrov et al. 2013 - Nature] (Supplementary Fig. S4).   		
Timing Progression	
Phylogenetic reconstruction from multiple samples of the same malignancy allows us to turn static 
snapshots of cancer genomes into the tumour evolutionary history by exploiting genomic intra-tumour 
heterogeneity (ITH) [11]. However, although phylogenetic trees inform on the relationship between 
different samples, estimating the exact chronology of the events without a temporal reference remains 
extremely challenging.		
In this exceptional case, the temporal reference is represented by the date of seeding along the 
needle tract that initiated the chest wall metastasis. This information allowed ‘calibration’ of the timing 
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for the whole tree and allowed us to follow the progression of the disease back in time, dating each 
ancestral node in the past history of the tumour. 		
The phylogenetic tree was inferred using a Maximum Likelihood approach and timed using a 
Bayesian phylogenomics framework, accounting for possible dynamic changes in mutational rate, to 
effectively “carbon date” the malignant progression and reveal the complete chronology of the 
different lesions in this patient (Fig. 3A; see Supplementary Table S5 for the list of mutations used the 
infer the phylogeny). In the field of evolutionary biology, this type of approach is widely used to time 
the onset of new species by exploiting temporal information from the fossil record [12].		
By considering the time of chest wall metastasis biopsy as time zero (September 2013) and the node 
between the chest wall biopsy and the lung biopsy (needle-tract seeding event) as a reference, we 
estimated that metastatic disease originated 9.26 years before, giving rise to the lung and thyroid 
metastases in parallel. The primary cancer instead originated between 9.96 and 13.17 years before 
(Fig. 3A and 3B; Supplementary Fig. S5). Hence, the primary adenocarcinoma emerged between five 
and eight years before clinical diagnosis (2000-2003). Despite the long latency between biological 
onset of the primary cancer and clinical presentation, within just one year from its inception the 
tumour began metastasising to the lung and to the thyroid where the metastasis grew within a Hurthle 
adenoma. Phylogenetic analysis revealed that the lung and thyroid metastasis were more closely 
related to one another than to the primary tumour. A schematic representation of the timeline of 
malignant progression is reported in Fig. 3B. 
 
Neo-antigen Load  
In order to test the contribution of anti-tumor immunity in regulating CRC evolution we applied the 
pipeline described in Supplementary Fig. S6 (see also supplementary methods) to the samples 
subjected to multi-region WGS. The analysis resulted in a remarkably low number of strong human 
leukocyte antigen (HLA) binders [(Colon= 42; Thyroid Met=4 and Lung Metastasis=6) Supplementary 
Table S6]. 	
Discussion		
Several studies have applied mathematical modelling to calculate the time-lapse between the onset of 
primary and metastatic spread [13, 14]. CRC modelling suggests that metastases can develop in less 
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than two years from the primary cancer [14]. However, these types of analysis remain difficult to 
interpret and hard to generalise due to the lack of temporal references. Here we exploited the 
occurrence of a needle tract metastasis to define the exact chronology of primary onset and 
metastatic spread. Our observations suggest that this process might be faster than expected, 
occurring within the initial twelve months from the primary onset. Similar patterns of early metastatic 
divergence have been reported in other tumour types using an analogous phylogenomic approach, 
where in the case of metachronous lesions, the time between primary and metastatic resection was 
used as a reference [15].		
Despite rapid metastatic transformation, our patient showed an indolent course of disease. How can 
we explain the discordance between the early metastatic dissemination and a relatively favourable 
prognosis in a patient with synchronous metastasis? The pattern of disease progression we observed 
is quite uncommon for a CRC patient but, in our opinion, does not account for the favourable 
outcome. Solitary lung metastases are observed in 11% of colon cancer patients; surgical resection 
can be curative in some cases but prognosis remains modest [16]. Thyroid and urinary tract 
metastasis are uncommon and are usually associated with poor prognosis and multi-metastatic 
disease. CRC metastases to a thyroid adenoma (tumour-to-tumour metastasis) are even less 
frequent and have always been associated with poor outcome [17]. Although the resection of both 
lung and the thyroid metastases might have contributed to the improved survival of our patient, the 
analysis of his molecular makeup suggests that a rather unusual pattern of low genomic instability 
may have contributed to the indolent course of disease. 		
In keeping with previous evidence from large-scale genomic studies [18], targeted sequencing 
showed clonal mutations in genes accounting for the “breakthrough” and “expansion” phase of the 
primary CRC [19] such as APC, CTNNB1, KRAS and P53. As expected, all these mutations were 
also detected in metastatic sites. In contrast, discrepancies between the primary and metastatic sites 
were observed for ADAMTS20 and AKAP9. In line with our observation, ADAMTS20 mutations were 
detected in a large series of primary CRC but not in their matching synchronous metastasis [6] 
suggesting this mutation might promote invasion of the primary cancer but might not be critical for cell 
fitness in metastatic sites. The anchor protein-coding gene AKAP9 has also been investigated in CRC 
and found to be up-regulated in CRC with nodal metastasis [20] suggesting a pro-metastatic role for 
this gene. The molecular pathology of our patient appears common to many other sporadic CRCs. 
Although the clonal or private mutations described above may have allowed our patient’s cancer cells 
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to metastasise and survive in different environments, this does not explain the slow pattern of 
progression, suggesting the reason for our patient’s indolent disease may lie elsewhere.		
Chromosomal (CIN) and Microsatellite (MSI) instability can be used to classify CRCs with different 
molecular and prognostic features [21]. Interestingly our patient showed no MSI and relatively few and 
clonal chromosomal aberrations, with a focal amplification in 13p12.2-12.3 encompassing the 
VEGFR2 and CDX2 loci, genes previously found over-expressed in synchronous versus 
metachronous metastatic CRC [22]. Different lines of evidence suggest that high CIN occurring at 
early stages of neoplastic transformation might represent a hallmark of aggressive behaviour [23, 24] 
thus the lack of it might explain the indolent course of disease observed in our patient. 
 
A final interesting point relates to the contribution of the tumour micro-environment to CRC evolution: 
low neo-antigen burden has been associated with worse prognosis in early-stage lung cancer [25]. In 
our case, the primary cancer displayed low number of neo-antigens and the lack of anti-tumour 
immunity against the primary cancer might explain the early metastatic spread.  
 
Genomic instability [24] and tumour-stroma interactions [26] represent synergic drivers of cancer 
progression. The genomic data suggest that in this patient these two hallmarks of cancer evolution 
might have been uncoupled: while the lack of immune response against the primary tumour might 
have promoted early cancer metastasis, the relative stability in genomic aberrations might account for 
the slow rate of progression. 
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Figure Legends 
 
Figure 1. Overview of clinical, radiological and pathological progression of a CRC patient. The 
patient underwent anterior resection for a pT4pN2 sigmoid cancer in November 2008. A lung nodule of 
unknown significance at the time of diagnosis was kept under surveillance and was subsequently 
proven to be metastatic in nature (biopsy in December 2011) and was resected in January 2012. An 
FDG-avid thyroid nodule was resected in August 2012 and showed a Hurtle adenoma containing foci 
of metastatic CRC. Two years after the lung biopsy, a chest wall mass on the site of previous lung 
biopsy was histologically confirmed and treated with chemo-radiotherapy. Six months after treatment 
the chest wall metastasis showed disease progression and a new site of metastasis along the left 
ureter was histologically confirmed during the insertion of a urinary stent. The timeline shows the 
dates that metastatic sites became apparent on imaging. Haematoxylin and Eosin (H&E) staining of 
primary and metastatic sites are shown. 
 
Figure 2. Histopathology and molecular profiling of the primary CRC and metastatic sites. (A) 
microscopy of the primary and metastatic sites including H&E staining, proliferation (nuclear Ki-67) 
and apoptosis (Caspase-3). (B) microscopy of the CRC lung metastasis that led to the needle tract 
seeding to the chest wall. Cells stained negative for TTF1 and positive for CDK20, CDX2 and CEA. 
(C) gross pathology and microscopy of the Hurtle Adenoma containing a CRC metastasis. 
Macroscopic examination showed the Hurtle adenoma containing a haemorrhagic or cystic area. 
Different magnifications show the Hurtle adenomatous cells (background large eosinophilic cells) with 
an invasive front of CRC metastasis. The dotted line indicates the border between the normal thyroid 
and the Hurtle adenoma. The black rectangle indicates the area of invasive CRC within the adenoma. 
(D) shows microscopy of the urothelial metastasis. H&E and CDK20 staining confirmed the colonic 
origin of the metastasis. (E) Drivers of CRC detected by WGS and validated by targeted exome 
sequencing. (F) Copy number changes in primary and metastatic sites. 
 
 Figure 3. Chronology of the patient’s CRC evolution. (A) Whole-genome sequencing of multiple 
lesions from the patient’s malignancy allowed phylogenetic reconstruction of the tumour tree. In the 
phylogenetic tree, dates within brackets indicate the time of clinical diagnosis whereas dates in bold 
highlight the estimated times of the different lesions. (B) Illustrative cartoon of the patient disease 
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progression and samples taken. At time 𝑡! the first colorectal cancer cell arose, giving rise to the 
primary tumour. At time 𝑡! the first metastatic clone emerged, giving rise to the lung metastasis, 
quickly followed by a second metastasis to the thyroid emerging at time 𝑡!. At time 𝑡!! the sample from 
the primary tumour was collected (resection) and analysed. During the lung biopsy, the needle tract 
seeding event spread cancer cells in the chest wall at time 𝑡!". A few days later, at time 𝑡!! the lung 
metastasis was resected and profiled. Finally at time 𝑡!"!  the chest wall metastasis was also sampled.	
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